entertainment -WSS

entertainment

author：entertainment 2025-09-27 12:47:31 - browse：664

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： Cancer drug shortages should be causing more outrage
Next article： Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

focus

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

Novo Nordisk to expand supply of Wegovy for U.S. patients

Medicare isn't yet testing food as medicine

Time to name cancers by genetics, not organ of origin, expert says

Vertex non

The real point of Kenneth Smith’s execution by nitrogen gas

knowledge

entertainment

Sign up for Morning Rounds

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Walensky prepares to leave CDC — and Congress — behind

CDC advisory group OKs chikungunya vaccine

Medicare proposal to cover medical devices draws a mixed reaction

Pfizer is about to make a big push in cancer. Will investors listen?

Drug repurposing or repositioning? The language matters

Doctor of U.S. President Joe Biden says he is fit for duty

Bright Health sells Medicare Advantage business to Molina

Congressmen charge Covid hearing ‘could have been an email’

focus

Pfizer is about to make a big push in cancer. Will investors listen?

Time to name cancers by genetics, not organ of origin, expert says

Children’s Hospital revives plan for pedestrian bridge

The real point of Kenneth Smith’s execution by nitrogen gas

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Medicare drug price negotiation’s day in court

focus

focus

hotspot

focus